法维拉韦治疗发热伴血小板减少综合征的研究进展和面临的挑战  

Research progress and challenges of favipiravir in the treatment of severe fever with thrombocytopenia syndrome

作　　者：刘亚萍 臧玮 彭学芳 田旭杰 LIU Yaping;ZANG Wei;PENG Xuefang(Drug and Equipment Department,Weihai Chest Hospital,Weihai 264200,China)

机构地区：[1]威海市胸科医院药械科,山东威海264200

出　　处：《中国处方药》2025年第5期107-110,共4页Journal of China Prescription Drug

基　　金：山东省医药卫生科技发展计划项目(202103080327)。

摘　　要：发热伴血小板减少综合征(SFTS)是由新型布尼亚病毒引起的一种新发传染病,该病现无特异性的治疗药物,目前治疗手段主要为对症治疗,常用的药物为抗病毒药物、糖皮质激素类药物、免疫球蛋白类药物等。本文总结国内外抗病毒药物法维拉韦治疗SFTS的研究进展,为临床使用法维拉韦治疗SFTS提供参考,展望法维拉韦正式投入到SFTS治疗面临的挑战。Severe fever with thrombocytopenia syndrome(SFTS)is an emerging infectious disease caused by novel bunyavirus.There is no specific treatment agent for this disease.At present,the main means of treatment is symptomatic treatments.Commonly used drugs are antiviral drugs,glucocorticoids,immunoglobulin drugs and so on.This paper reviewed the research progress of antiviral drug favipiravir in the treatment of SFTS at home and abroad for guiding the clinical use of favipiravir in the treatment of SFTS,and providing reliable reference,looking forward to the challenges faced by favipiravir in the treatment of SFTS.

关 键 词：法维拉韦 发热伴血小板减少综合征 研究进展 

分 类 号：R73[医药卫生—肿瘤]